AbbVie Acquires Apogee for $10.9 Billion
AbbVie (ABBV) announced the acquisition of Apogee Biotechnology for $10.9 billion in cash. The deal adds a promising experimental drug to AbbVie's pipeline, but questions remain about whether the price is justified.
Key Numbers
AbbVie (ABBV) announced the acquisition of Apogee Biotechnology in an all-cash deal valued at $10.9 billion. The acquisition aims to bolster AbbVie's pipeline with a promising experimental drug expected to achieve blockbuster sales. The deal is expected to close in the first half of 2026, pending regulatory approvals.
Deal Details
| Item | Detail |
|---|---|
| Total Value | $10.9 billion in cash |
| Price per Share | Not yet disclosed |
| Premium | Not yet specified |
| Payment Method | All cash |
| Regulatory Approvals | Pending |
Rationale for the Deal
AbbVie seeks to strengthen its drug pipeline, especially as patents for its flagship drug Humira expire. Apogee's experimental drug targets a rare disease and has high commercial potential, which could offset some lost revenue.
Regulatory Challenges
The deal may face antitrust scrutiny, particularly in the US and Europe. Additionally, FDA approval for the experimental drug is not guaranteed.
Impact on Stocks
AbbVie's stock (ABBV) showed little change after the announcement, as investors assess the deal's value. Regeneron (REGN) was not directly affected, as there is no clear link between the two companies.
Frequently Asked Questions
Found this useful? Share it